Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sacubitril/Valsartan vs Entresto in Healthy Volunteers
NCT06922253Phase 1Completed
- Sponsor
- Humanis
- Start
- Dec 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sacubitril and valsartan in chronic heart failure (CHF) (2 arms), sponsored by Humanis. Primary endpoints: Peak Plasma Concentration at 48 hours and Area Under the Curve from time zero to time of last measurable concentration at 48 hours. Started Dec 2024; status: completed.
02
Drugs
sacubitrilvalsartan
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT06922253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922253.